Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 239

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 239
---
 success will depend in part
on our ability to obtain and maintain patent protection for our formulations and technologies and to prevent third parties from infringing
upon our proprietary rights. We must also operate without infringing upon patents and proprietary rights of others, including by obtaining
appropriate licenses to patents or other proprietary rights held by third parties, if necessary. The primary means by which we will be
able to protect our formulations and technologies from unauthorized use by third parties is to obtain valid and enforceable patents that
cover them. However, the applications we have filed or may file in the future may never yield patents that protect our inventions and
intellectual property assets. Failure to obtain patents that sufficiently cover our formulations and technologies would limit our protection
against other compounding pharmacies and outsourcing facilities, generic drug manufacturers, pharmaceutical companies and other parties
who may seek to copy our products, produce products substantially similar to ours or use technologies substantially similar to those
we own. We have made, and expect to continue to make, significant investments in certain of our proprietary formulations prior to the
grant of any patents covering these formulations, and we may not receive a sufficient return on these investments if patent coverage
or other appropriate intellectual property protection is not obtained and their competitiveness and value decreases.

The patent and intellectual property
positions of pharmacies and pharmaceutical companies, including ours, are uncertain and involve complex legal and factual questions.
There is no guarantee that we have developed or obtained or will in the future develop or obtain the rights to products or processes
that are patentable, that patents will issue from any pending applications or that claims allowed will be sufficient to protect the technology
we have developed or may in the future develop or to which we have acquired or may in the future acquire development rights. In addition,
we cannot be certain that patents issued to us will not be challenged, invalidated, infringed or circumvented, including by our competitors,
or that the rights granted thereunder will provide competitive advantages to us. In certain instances, we have acquired products that
are patented and have been subject to prior litigation challenging the validity of certain patents related to those products. In some
situations, the litigation resulted in settlement agreements that have allowed generic manufacturers to license the patent rights related
to certain products and allowing the generic manufacturer to enter the market prior to patent expiration associated with the branded
product.

We also rely on unpatented trade
secrets and know-how and continuing technological innovation in order to develop our products, formulations, which we seek to protect,
in part,